RECRUITING

Amplitude Titration to Improve ECT Clinical Outcomes

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

A randomized controlled trial will compare hippocampal neuroplasticity, antidepressant, and cognitive outcomes between individualized amplitude and fixed 800 mA amplitude ECT in older depressed subjects (n = 25 per group, n = 50 total). Relative to fixed 800 mA ECT: H1: Individualized amplitude arm will have improved RUL antidepressant outcome (IDS-C30 response rates and reduced BT electrode placement switch at V2). H2: Individualized amplitude arm will have improved cognitive outcomes (DKEFS-Verbal Fluency

Official Title

Amplitude Titration to Improve ECT Clinical Outcomes Randomized Clinical Trial

Quick Facts

Study Start:2023-09-14
Study Completion:2026-01-30
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05699226

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:50 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Diagnosis of major depressive disorder or bipolar II
  2. * Clinical indications for ECT with right unilateral electrode placement
  1. * Defined neurological or neurodegenerative disorder (e.g., traumatic brain injury, epilepsy, Alzheimer's disease)
  2. * Other psychiatric conditions (e.g., schizophrenia, bipolar I disorder)
  3. * Current drug or alcohol use disorder (except for nicotine)
  4. * Contraindications to MRI.

Contacts and Locations

Study Contact

Chris Abbott, MD
CONTACT
5052720406
cabbott@salud.unm.edu
Megan Lloyd, MS
CONTACT
‭(505) 272-3507‬
meglloyd@salud.unm.edu

Principal Investigator

Chris Abbott, MD
PRINCIPAL_INVESTIGATOR
University of New Mexico

Study Locations (Sites)

University of New Mexico Health Science Center
Albuquerque, New Mexico, 87110
United States

Collaborators and Investigators

Sponsor: University of New Mexico

  • Chris Abbott, MD, PRINCIPAL_INVESTIGATOR, University of New Mexico

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-09-14
Study Completion Date2026-01-30

Study Record Updates

Study Start Date2023-09-14
Study Completion Date2026-01-30

Terms related to this study

Additional Relevant MeSH Terms

  • Depression
  • ECT
  • Cognitive Change